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SUMMARY
The World Health Organization had endorsed Xpert® MTB/RIF (Xpert) as the initial diagnostic
for multidrug-resistant tuberculosis (TB) or TB suspects co-infected with the human
immunodeficiency virus. We investigated an unexpected case of rifampicin (RMP) resistance on
Xpert using repeat Xpert, smear microscopy, MTBDRplus assay, culture, drug susceptibility
testing, spoligotyping and rpoB gene sequencing. A false-positive result was most likely, given the
wild type rpoB gene sequence and exclusion of both mixed infection and mixture of drug-
susceptible and drug-resistant populations. When decentralising Xpert, test performance
characteristics need to be understood by health care workers and methods of confirmation of RMP
resistance need to be accessible.
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MULTIDRUG-RESISTANT tuberculosis (MDR-TB) threatens global TB control. The
World Health Organization (WHO) has endorsed the Xpert® MTB/RIF test (Xpert;
Cepheid, Inc, Sunnyvale, CA, USA) as the initial diagnostic for those at risk of MDR-TB or
human immunodeficiency virus (HIV) associated TB.1 Rapid diagnosis of rifampicin (RMP)
resistance could reduce the morbidity, mortality and transmission of drug-resistant TB.
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The first large clinical Xpert validation study reported 100% specificity for the detection of
RMP resistance after resolution of discordances by rpoB genotyping.2 In a subsequent
multicentre study, the specificity for RMP resistance was found to be lower (98.3%).3
We report a comprehensive investigation of an unexpected case of RMP resistance on Xpert
and discuss the implications for patient management.
CASE REPORT
In April 2010, a 49-year-old HIV-infected (CD4 count 169 cells/mm3) male presented to a
primary care clinic in Johannesburg, South Africa, with a 6-week history of cough. He had
no TB treatment history, but had recently moved from Msinga, KwaZulu-Natal, where an
outbreak of extensively drug-resistant TB had occurred in 2006.
An Xpert assay was positive for RMP-resistant Mycobacterium tuberculosis, with ΔCt Max
exceeding 3.5 cycles for probe B (first generation software). A repeat Xpert assay indicated
RMP-susceptible M. tuberculosis complex (MTC). Anti-tuberculosis treatment and
antiretroviral treatment were initiated while awaiting confirmatory results. The patient
successfully completed 6 months of first-line anti-tuberculosis treatment.
The discrepancy in the above results led to a full investigation, for which the patient gave
informed consent. Smear microscopy was negative or scanty for acid-fast bacilli, except for
induced sputum (Table 1). Cultures (BACTEC Mycobacteria Growth Indicator Tube 960,
BD, Sparks, MD, USA), GenoType® MTBDRplus (Hain LifeScience GmbH, Nehren,
Germany) and Xpert assays were positive for MTC. No assays indicated technical errors.
The first and third Xpert assays indicated RMP resistance, based on a delay in probe B (Ct
max 4.9 and 4.1); the second Xpert was RMP-susceptible. MTBDRplus, performed directly
on decontaminated sputum to avoid RMP-susceptible strain overgrowth during culture,
showed RMP-susceptible MTC for all three specimens. Phenotypic drug susceptibility
testing (indirect proportion method on 7H10 media containing 1.0 μg/ml RMP) also
demonstrated RMP susceptibility. DNA sequencing confirmed wild type rpoB sequences in
all cultures.4 Spoligotyping demonstrated an identical spoligotyping pattern (ST4) for all
three cultures.5
An administrative error was considered unlikely, as RMP resistance on Xpert was detected
on independent specimens collected on 2 different days. All three cultures shared the same
spoligotype pattern (Table 2), and no drug-resistant TB patient was diagnosed or treated at
the clinic at that time. Mixed infection with multiple M. tuberculosis strains was unlikely, as
spoligotyping demonstrated the absence of a background hybridising pattern and an identical
pattern (ST4) in all three isolates. Heteroresistance, i.e., mixed infection with resistant and
susceptible populations of the same M. tuberculosis strain, was unlikely, as no growth was
observed in any of the RMP-containing plates of isolates 1 and 2 (isolate 3 was
contaminated), and careful examination of the DNA sequence chromatogram failed to
identify underlying peaks.
DISCUSSION
A false-positive result was the most likely cause of the observed discrepancies, given the
wild type rpoB gene sequence, exclusion of mixed infection with multiple M. tuberculosis
strains and exclusion of a mixture of drug-susceptible and drug-resistant populations.
Despite these comprehensive investigations, heteroresistance could not be confidently
excluded as unprocessed sputum or cartridge amplicons were not sequenced. Others have
reported false-positive RMP results;3,6,7 Marlowe et al. also identified a specimen that was
repeatedly RMP-resistant on Xpert but susceptible on phenotypic DST and rpoB
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sequencing.6 In contrast, Theron et al. identified six RMP-resistant cases on Xpert, five of
which were susceptible on phenotypic DST, although five were genotypically resistant by
sequencing and/or MTBDRplus.7 The complexity of these investigations demonstrates the
difficulty in confidently distinguishing false-positive from true-positive RMP-resistant
results, particularly in clinical practice.
In response to reports of false-positive RMP-resistant results, the manufacturer performed a
root cause analysis, which identified the bead manufacturing scale-up and annealing
temperature requirements of probe B as potential causes. Solutions include improved bead
reconstitution, a software change and adjustment of probe B to increase robustness.8 The
revised assay is being evaluated. While fewer false-positive results can be expected
following assay improvements, an almost perfect (close to 100%) assay specificity will be
required before high positive predictive values are achieved in TB suspects in HIV endemic,
low MDR-TB prevalence areas.1,9
The assay performance has important implications for patient management. The WHO
recommends a confirmatory DST in patients with RMP resistance on Xpert. Use of the
MTBDRplus assay will lead to a median delay between initial diagnosis and availability of
results at the clinic of 40 days,3 while phenotypic DST will result in even longer delays.3
These delays give rise to the clinical dilemma of which regimen to start. The WHO
recommends MDR-TB treatment in patients diagnosed with RMP resistance on Xpert, but
Xpert can be performed at a clinic or microscopy centre, a setting that rarely has access to
second-line drugs. Should health care workers start first-line treatment, or should they defer
starting any treatment while awaiting the patient’s arrival at the MDR-TB treatment centre?
Starting first-line drugs could pose the risk of amplification of resistance to ethambutol or
pyrazinamide,10 limiting future treatment options, while not starting any drugs poses
infection control issues and increased risk of death. In patients with low pretest probability
living in an area with poor access to MDR-TB treatment, clinicians may reserve the
currently limited MDR-TB treatment capacity for those with confirmed MDR-TB or try to
balance the risks and benefits of different regimens based on risk assessment for MDR-TB,
type of confirmatory test available (‘rapid’ MTBDRplus or slower phenotypic DST), ease of
access to MDR-TB treatment, financial burden of referral for MDR-TB treatment (transport
cost and loss of employment during hospitalisation), risk of transmission to vulnerable
individuals (young children or HIV-positive relatives), patient’s HIV status, risk of death
while awaiting confirmatory results, risk of toxicity from second-line anti-tuberculosis
drugs, and risk of amplification of drug resistance.
In conclusion, this report highlights the need for health care workers’ understanding of assay
performance characteristics when decentralising the diagnosis of drug-resistant TB. These
issues should not, however, diminish enthusiasm for the Xpert assay.
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Table 1












Day 0 Negative for AFB Not performed Not performed NA
Day 1 Scanty positive Not performed Contaminated Not performed



















Not performed Positive for
 M.
tuberculosis





























Day 16 Positive+ RMP-resistant
 M. tuberculosis
Not performed Not performed
*
Number of days represents time since presentation to clinic with symptoms of TB; first-line treatment was initiated on Day 9.
†
Classification of smear microscopy: scanty positive = 1 AFB/100 immersion fields; positive + = 10–99 AFB/100 immersion fields; positive ++ =
>100 AFB/100 immersion fields.
‡
GenoType MTBDRplus assay (Hain LifeScience, GmbH, Nehren, Germany).
RMP = rifampicin; AFB = acid-fast bacilli; NA = not applicable; INH = isoniazid; wt = wild type.
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Table 2
Investigation of main hypothesis (false-positive RMP resistance) and alternative hypotheses
Hypothesis Investigation Result Conclusion
Main hypothesis
 False-positive RMP resistance
  result according to the




 M. tuberculosis complex
Wild-type sequence for RRDR






Collection and on-site processing
 of 3 samples on 3 different days
Spoligotyping of three samples
 to confirm same strain of
 M. tuberculosis
2 of 3 samples RMP-resistant,
 one RMP-susceptible
Same pattern (ST4) for all three
 cultures
No administrative error
Infection with multiple strains Spoligotyping of 3 positive
 cultures
No evidence of multiple strains Infection with multiple
 strains unlikely
Mixed population of
 susceptible and resistant
 strains (heteroresistance)
Growth on 7H10 media
 containing 1.0 μg/ml RMP
No growth on any of the plates Heteroresistance unlikely
*
MTBDRplus assay (Hain LifeScience GmbH, Nehren, Germany).
RMP = rifampicin; RRDR = RMP resistance-determining region.
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